The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

http://www.wikidata.org/entity/Q37085219

about

Osimertinib making a breakthrough in lung cancer targeted therapy Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Novel immunotherapy in the treatment of advanced non-small cell lung cancer.Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.Recent advances in targeted advanced lung cancer therapy in the elderly.The cost and value of cancer drugs - are new innovations outpacing our ability to pay?Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.An in Vitro Assay of hERG K + Channel Potency for a New EGFR Inhibitor FHND004.Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non-Small Cell Lung Cancer.An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors

P2860

Q28079689-DF9B19FC-88EC-41D1-ACDE-3A360E96672A Q37060709-1C3E47CF-FFB8-44F2-857C-BF6A126366D2 Q38953461-EA9DA4C6-2EAE-4596-A624-5895AFAFFEA1 Q39280914-D9FC9060-7D6C-4432-8647-B8E82A79BD37 Q40143039-3B3890B2-8F81-482F-BE74-D08E164C4CA8 Q42392412-4B01C672-E60F-4AB9-AE75-2B85192A78C7 Q47124054-0491FD91-2DD4-44D1-82C8-3473FB0845A5 Q55175160-B50E8165-CF0C-444B-A8E1-2BB0B92CE3C9 Q55230293-7F455F45-5306-4C8D-930D-E421E06C1581 Q58698813-2487CB8F-990C-4EB5-87B4-35CA7E96351F

P2860

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

http://www.wikidata.org/entity/Q37085219

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The safety and efficacy of osi ...... ve non-small-cell lung cancer.

@en

The safety and efficacy of osi ...... ve non-small-cell lung cancer.

@nl

type

label

The safety and efficacy of osi ...... ve non-small-cell lung cancer.

@en

The safety and efficacy of osi ...... ve non-small-cell lung cancer.

@nl

prefLabel

The safety and efficacy of osi ...... ve non-small-cell lung cancer.

@en

The safety and efficacy of osi ...... ve non-small-cell lung cancer.

@nl

P1433

Q37085219-62F0F4AB-FA1E-4174-92B2-70636075ABAD

P1476

Q37085219-CF28D2AD-3347-4FF9-B085-333E3EA3E928

P2093

Q37085219-A4D3F231-BCB8-4391-BDA7-3FE23ED30B96

Q37085219-D2ADE4FF-FEC0-422F-A367-6AEEC42891C6

P2860

Q37085219-04946D1D-68D5-4CDD-88AC-00FD4EB7E6CC

Q37085219-0817BDFC-BF21-4378-B1B7-7110D0EEAA28

Q37085219-0C8CE3EE-3F0F-437F-9FEA-84524A5124DE

Q37085219-1549E00A-4969-463B-89D9-982CC43D0DFF

Q37085219-1D6DE417-55B6-4692-9453-1558C7BA570C

Q37085219-1E070420-C89E-4D87-9967-26579020C543

Q37085219-2D892B53-5743-44F1-8C3F-027D3870312C

Q37085219-33C8DF5B-51D9-49CC-9AF5-1FE24BA50600

Q37085219-3729C9D8-6276-4052-BC45-1E6C7758B7DF

Q37085219-37575EEB-9AE7-4E17-8984-D0C0FE2F6512

P304

Q37085219-462A90EF-AAF7-4047-B8EF-E2EA7730FB90

P31

Q37085219-C57486BA-36CC-4EEA-B933-1C462AA0CFD4

P356

Q37085219-F8D9582C-EB60-4A14-8AC4-FA9732320119

P433

Q37085219-7C7A61D0-6BC2-4AB3-90BB-1E228A96284D

P478

Q37085219-44802CF4-FF29-4306-8CF7-83853CDDAAC7

P50

Q37085219-03AEBBDB-14A8-4582-8AC8-82E9BD200040

P577

Q37085219-6FDCA364-DD01-457F-843E-7E62601F4681

P698

Q37085219-BB288DB2-CE58-476A-94CA-0AEF0982344E

P932

Q37085219-B0CB85CE-3045-488B-943E-D12083A2EC1F

P356

14737140.2016.1162103

P1433

Expert Review of Anticancer Therapy

P1476

The safety and efficacy of osi ...... ve non-small-cell lung cancer.

@en

P2093

Xin Gao

http://www.w3.org/2001/XMLSchema#string

Xiuning Le

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

P304

383-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2016.1162103

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26943236

http://www.w3.org/2001/XMLSchema#string

P932

4940973

http://www.w3.org/2001/XMLSchema#string